GLP-1 Receptor Agonists: A Turning Point in Obesity Treatment

2026 is poised to be a pivotal year in the fight against obesity, as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) continue to revolutionize management strategies. These medications, initially developed for type 2 diabetes, have demonstrated significant benefits for weight loss and related health conditions. The global weight-loss medications market is projected to reach US$150 billion by 2035, reflecting the growing demand and recognition of obesity as a chronic disease.

The Obesity Epidemic: A Global Challenge

More than one billion people worldwide live with obesity, and the prevalence is rapidly increasing, particularly in low- and middle-income countries. The World Health Organization (WHO) defines obesity as having a Body Mass Index (BMI) of 30 or higher in adults. In 2024, obesity was associated with 3.7 million deaths globally, and without intervention, the number of people affected is projected to double by 2030. Beyond the health impacts, the economic cost of obesity is predicted to reach US$3 trillion annually by 2030.

How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists are a class of medications that mimic the effects of the naturally occurring GLP-1 hormone. They work by:

• Lowering blood sugar levels
• Promoting weight loss
• Reducing the risk of heart and kidney complications
• Potentially lowering the risk of early death in people with type 2 diabetes

Research, including a narrative review published in eClinicalMedicine, highlights the substantial weight loss and metabolic benefits offered by GLP-1 RAs compared to alternative treatments.

WHO’s Modern Guidelines and Essential Medicines List

Recognizing the growing global health challenge, the World Health Organization (WHO) released its first guideline on the use of GLP-1 therapies for treating obesity as a chronic, relapsing disease in December 2025. In September 2025, WHO added GLP-1 therapies to its Essential Medicines List for managing type 2 diabetes in high-risk groups. The new guideline provides conditional recommendations for using these therapies as part of a comprehensive approach that includes healthy diets, regular physical activity, and support from healthcare professionals.

Challenges and Future Directions

Despite the promise of GLP-1 RAs, challenges remain. High costs, limited production capacity, and supply-chain constraints have resulted in inequitable access to these medications. Ongoing research is focused on addressing these issues and exploring new indications for GLP-1 RAs, as well as investigating future directions in obesity management.

Key Takeaways

• GLP-1 receptor agonists represent a significant advancement in obesity treatment.
• Obesity is a global health crisis with increasing prevalence and substantial health and economic consequences.
• The WHO has issued guidelines and added GLP-1 therapies to its Essential Medicines List to address this challenge.
• Equitable access to these medications remains a critical concern.